Liu Junning, Zhang Guangnian, Yang Linfeng, Yan Duan, Yu Jiahui, Wei Song, Li Jijiang, Yi Pengsheng
Department of Hepato-Biliary-Pancreases II, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, China.
Department of Hepato-Biliary-Pancreases II, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, China.
Eur J Surg Oncol. 2024 Jul;50(7):108427. doi: 10.1016/j.ejso.2024.108427. Epub 2024 May 20.
Salvage liver transplantation (SLT) is an effective treatment option for recurrent hepatocellular carcinoma (rHCC) following primary curative treatment (CUR). However, its efficacy remains controversial compared to that of CURs, including repeat liver resection (RLR) and local ablation. This meta-analysis compared the efficacy and safety of these procedures.
A systematic literature search of the PubMed, Embase, Web of Science, and Cochrane Library databases for studies investigating SLT and CUR was performed. Outcome data, including overall and disease-free survival, tumor response, and operative and postoperative outcomes, were independently extracted and analyzed by two authors using a standardized protocol.
Fifteen cohort studies comprising 508 and 2050 patients with rHCC, who underwent SLT or CUR, respectively, were included. SLT achieved significantly longer overall survival than both CUR (hazard ratio [HR]: 0.56, 95 % confidence interval [CI]: 0.45-0.68; I = 34.6 %, p = 0.105) and RLR (HR: 0.64, 95 % CI: 0.49-0.84; I = 0.0 %, p = 0.639). Similar significantly better survival benefits were observed compared with CUR (HR: 0.30, 95 % CI: 0.20-0.45; I = 51.1 %, p = 0.038) or RLR (HR: 0.31, 95 % CI: 0.18-0.56; I = 65.7 %, p = 0.005) regarding disease-free survival. However, SLT resulted in a longer operative duration and hospital stay, larger amount of blood loss, higher rate of transfusion and postoperative morbidity, and slightly higher postoperative mortality than CUR.
SLT was associated with better long-term survival than CUR or RLR in patients with rHCC after primary curative treatment.
挽救性肝移植(SLT)是原发性肝癌根治性治疗(CUR)后复发性肝细胞癌(rHCC)的一种有效治疗选择。然而,与包括再次肝切除(RLR)和局部消融在内的CUR相比,其疗效仍存在争议。本荟萃分析比较了这些手术的疗效和安全性。
对PubMed、Embase、Web of Science和Cochrane图书馆数据库进行系统文献检索,以查找研究SLT和CUR的研究。结局数据,包括总生存期和无病生存期、肿瘤反应以及手术和术后结局,由两位作者使用标准化方案独立提取和分析。
纳入了15项队列研究,分别包括508例和2050例接受SLT或CUR的rHCC患者。SLT的总生存期显著长于CUR(风险比[HR]:0.56,95%置信区间[CI]:0.45–0.68;I² = 34.6%,p = 0.105)和RLR(HR:0.64,95% CI:0.49–0.84;I² = 0.0%,p = 0.639)。在无病生存期方面,与CUR(HR:0.30,95% CI:0.20–0.45;I² = 51.1%,p = 0.038)或RLR(HR:0.31,95% CI:0.18–0.56;I² = 65.7%,p = 0.005)相比,观察到类似的显著更好的生存获益。然而,与CUR相比,SLT导致手术时间更长、住院时间更长、失血量更大、输血率和术后发病率更高,术后死亡率略高。
在原发性肝癌根治性治疗后的rHCC患者中,SLT与比CUR或RLR更好的长期生存相关。